Clinical Trial Update: Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral sildenafil to improve exercise capacity, dyspnea, and cardiopulmonary function in COPD; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: University of Alberta | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: RECRUITING